The global biomarkers market is a dynamic sector at the intersection of medicine and technology, playing a pivotal role in disease diagnosis, prognosis, and therapeutic advancements. Biomarkers are measurable indicators that provide essential information about physiological and pathological processes within the body. This market encompasses a wide array of biomarkers, ranging from genetic and proteomic markers to imaging biomarkers, facilitating precision medicine and personalized treatment approaches. As the healthcare industry continues to embrace biomarker-driven strategies, the global biomarkers market is poised for substantial expansion, contributing significantly to the advancement of diagnostic and therapeutic practices worldwide.
Access Full Report:- https://www.databridgemarketresearch.com/de/reports/global-biomarkers-market
Data Bridge Market Research analyses that the Global Biomarkers Market which was USD 43.13 million in 2022, is expected to reach USD 153.34 million by 2030, and is expected to undergo a CAGR of 14.90% during the forecast period of 2023-2030. Heightened investment in biomarker research, driven by scientific advancements and expanded understanding of their therapeutic potential, is transforming healthcare. Enabling early detection, precise diagnosis, and informed treatment decisions, biomarkers attract substantial investments from pharmaceuticals, biotech firms, research institutes, and governmental bodies, fostering market growth.
Key Findings of the Study
Rising burden of cancer is expected to drive the market's growth rate
Biomarkers play a pivotal role in addressing the escalating cancer burden through early detection, precise diagnosis, and treatment monitoring. They enable timely intervention when cancer is more treatable. Techniques such as blood tests and liquid biopsies detect specific biomarkers associated with malignancies, aiding in screening. Furthermore, biomarkers predict treatment responses, guiding healthcare professionals in selecting tailored therapies such as targeted drugs or immunotherapies. This personalized approach improves outcomes and underscores the indispensable contribution of biomarkers in the comprehensive management of cancer.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Safety, Efficacy, and Validation), Application (Diagnostics Development, Drug Discovery and Development, Personalized Medicine, Disease-Risk Assessment, and Others), Product Type (Consumables, Services, and Software), Technology (Safety Biomarkers, Efficacy Biomarkers, and Validation Biomarkers), Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
Enzo Biochem Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer Inc. (U.S.), QIAGEN (Germany), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Epigenomics AG (Germany), MESO SCALE DIAGNOSTICS, LLC (U.S.), EKF Diagnostics Holdings plc (U.K.), General Electric Company (U.S.), Nexus- Dx (U.S.), LifeSign LLC (U.S.), F.Hoffman- La Roche Ltd (Switzerland), Thermo Fischer Scientific Inc. (U.S.), Eurofins Scientific (Luxembourg), Abbott (U.S.), Charles River Laboratories International Inc. (U.S.), Sino Biological, Inc. (China), and CENTOGENE N.V. (Germany)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global biomarkers market is segmented based on type, application, product type, technology, and indication.
- On the basis of type, the global biomarkers market is segmented into safety, efficacy, and validation
- On the basis of application, the global biomarkers market is segmented into diagnostics development, drug discovery and development, personalized medicine, disease-risk assessment, and others
- On the basis of product type, the global biomarkers market is segmented into consumables, services, and software
- On the basis of technology, the global biomarkers market is segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers
- On the basis of indication, the global biomarkers market is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others
Major Players
Data Bridge Market Research recognizes the following companies as the major global biomarkers market players in global biomarkers market are General Electric Company (U.S.), Nexus- Dx (U.S.), LifeSign LLC (U.S.), F.Hoffman- La Roche Ltd (Switzerland), Thermo Fischer Scientific Inc. (U.S.), Eurofins Scientific (Luxembourg), Abbott (U.S.), Charles River Laboratories International Inc. (U.S.), Sino Biological, Inc. (China), and CENTOGENE N.V. (Germany)
Market Developments
- In February 2022, the FNIH Biomarkers Consortium initiated the "Neurofilament as a Fluid Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD)" project. This initiative aims to pinpoint optimal blood tests for detecting a crucial protein linked to early signs of rare neurodegenerative diseases. The project underscores the significance of advancing biomarker research to enhance early diagnosis and intervention in familial frontotemporal degeneration and related conditions
- In February 2022, OncoDNA unveiled the OncoDEEP kit, a genomic and therapeutic solution. Tailored for laboratories equipped with NGS capabilities, the kit provides a seamless workflow for comprehensive biomarker testing. It facilitates robust data analysis, empowering oncologists to make informed decisions and offer personalized treatments to cancer patients based on precise genetic insights
- In December 2021, CENTOGENE NV was honored for its groundbreaking AI-powered biomarker platform, CentoMetabolome. This internally developed platform has the transformative capability to expedite novel biomarker identification, reducing research timelines from months to mere days. The CentoMetabolome platform offers comprehensive metabolome screening, identifies potential biomarker candidates, and enhances knowledge on drug efficacy, showcasing its potential to significantly advance biomarker discovery and drug development processes
- In May 2021, QIAGEN N.V. introduced an FDA-approved tissue companion diagnostic for detecting the KRAS G12C mutation in NSCLC tumors. This strategic move enhances the company's lung cancer precision medicine portfolio, marking a significant step forward in advancing diagnostic capabilities. The new diagnostic tool aligns with QIAGEN's commitment to providing cutting-edge solutions for personalized medicine in the realm of lung cancer treatment
Regional Analysis
Geographically, the countries covered in the global biomarkers market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in the global biomarkers market during the forecast period 2023-2030
North America dominates the global biomarkers market, attributed to extensive utilization in personalized medicine. The region's advanced healthcare infrastructure emphasizes biomarkers' role in tailoring treatments. The prevalence of chronic diseases fuels demand, and technological innovations propel biomarker adoption. With a focus on precision medicine, North America leads in integrating biomarkers for early diagnosis, prognosis, and therapeutic guidance. This dominance underscores the region's forefront position in advancing healthcare through the strategic incorporation of biomarker technologies.
Asia-Pacific is estimated to be the fastest-growing region in the global biomarkers market during the forecast period 2023-2030
Asia-Pacific is expected to dominate the global biomarkers market from 2023 to 2030, fueled by the rising global cancer burden. The region experiences notable growth attributed to increased research endeavors, reflecting a growing demand for quality healthcare. As the epicenter of these advancements, Asia-Pacific stands poised for substantial market expansion, contributing significantly to the global landscape in the coming years.
For more detailed information about the global biomarkers market report, click here – https://www.databridgemarketresearch.com/de/reports/global-biomarkers-market
